Investor Backing & Capital Strength:
Recent late‑stage financing of $150M in March 2026 and a reported ~$3B valuation signal strong external capital support and balance‑sheet flexibility. Multiple reputable outlets and independent trackers corroborate the funding milestone and late‑stage status.
Strong Revenue Growth:
Trade coverage and company statements cite approximately a $1B annual revenue run rate around the Series D, indicating rapid top‑line expansion. These figures are directional but echoed across multiple reputable sources.
Strategic Partnerships:
Expansion of integrations with health plans and new employer offerings points to deepening commercial relationships beyond direct‑to‑consumer. Reports describe broad insurer participation and expanded enterprise distribution.
